Research programme: MHC class II gene modulators - Debiopharm

Drug Profile

Research programme: MHC class II gene modulators - Debiopharm

Alternative Names: Debio 0406; p53-69

Latest Information Update: 14 Jul 2010

Price : $50

At a glance

  • Originator GPC Biotech AG
  • Developer Debiopharm
  • Class Small molecules
  • Mechanism of Action MHC class II gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 12 Jun 2007 Preclinical development is ongoing
  • 17 Dec 2004 GPC Biotech's small molecule MHC class II antagonists programme has been licensed to Debiopharm worldwide
  • 29 Aug 2002 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top